High blood pressure before age 40 tied to earlier strokes, heart disease
(Reuters Health) – People who develop high blood pressure before age 40 have a higher risk of heart disease and strokes in middle age, two new studies suggest. One of…
J&J makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z
TOKYO (Reuters) – U.S. healthcare conglomerate Johnson & Johnson (JNJ.N) said on Tuesday it is acquiring all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd (4924.T) that it…
Sanofi drug Dupixent wins FDA approval to treat asthma
(Reuters) – France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types…
AbbVie CFO Chase stepping down, to retire by mid-year 2019
(Reuters) – AbbVie Inc (ABBV.N) said on Friday that Chief Financial Officer William Chase is retiring in mid-2019 and named its controller, Robert Michael, his immediate successor as CFO. FILE…
EMA committee recommends restrictions on fluoroquinolone, quinolone antibiotics
(Reuters) – The European Medicines Agency’s risk assessment committee has recommended restrictions on the use of broad-spectrum antibiotics fluoroquinolone and quinolone following a review of side effects, the EMA said…
Lilly’s diabetes drug data impresses, hurts rival Novo’s shares
(Reuters) – Eli Lilly and Co (LLY.N) said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record…
Insmed’s treatment-resistant lung disease drug gets FDA approval
(Reuters) – The U.S. Food and Drug Administration on Friday approved Insmed Inc’s lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the…
Drug shortages may add $230 million to annual U.S. drug costs
(Reuters Health) – Prescription drug shortages may drive up prices twice as much as they would rise with medicines in abundant supply, adding $230 million a year to U.S. drug…
Diabetes drugs less affordable, less available in lower income countries
(Reuters Health) – People who live in low-income and middle-income countries may have a harder time finding and affording essential medicines for diabetes than residents of wealthier nations, a recent…
EU approves fifth copy of AbbVie’s $18 billion drug Humira
LONDON (Reuters) – Europe has approved a fifth copy of AbbVie’s $18-billion-a-year biologic drug Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech…